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Abstract
Background: The fate of a microscopic positive ductal margin (MPDM) of extrahepatic bile duct (EHBD)
cancer is unclear. The purpose of this study was to analyse the clinicopathological features of EHBD
cancer with MPDM and to identify the prognostic factors associated with survival.
Methods: Between 1995 and 2007, a retrospective analysis of 464 patients who had undergone surgical
resection for EHBD cancer was conducted. Clinicopathological factors likely to influence survival were
assessed using univariate and multivariate analysis.
Results: One hundred twenty-four patients had MPDM which included invasive carcinoma (IC) (n =85)
and carcinoma in situ (CIS)/ high-grade dysplasia (HGD) (n = 39). The median survival (MS) of R0, R1 as
CIS/ HGD, and R1 as IC were 41 months, 29 months, and 18 months, respectively. Adverse prognostic
factors were ‘IC’ on the resection margin [HR = 1.66, 95% confidence intervals (CIs) 1.06–2.59, P = 0.026],
and no use of adjuvant chemoradiotherapy (HR = 1.57, 95% CIs 1.04–2.39, P = 0.033). Adjuvant
chemoradiotherapy was beneficial in patients with MPDM as IC (5-year survival rate 19.7 compared with
2.8%, P = 0.011).
Conclusions: The presence of MPDM is an important prognostic factor in EHBD cancer. When a ductal
resection margin is positive, discrimination between ‘IC’ and ‘CIS/ HGD’ is important.
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Introduction
A surgical resection has been the mainstay of curative treatment
for extrahepatic bile duct (EHBD) cancer. Overall, 5-year survival
rates (5YSR) of 20–35% have been reported after resection of
EHBD cancer.1–3 In addition, most patients who undergo a resec-
tion die of local tumour recurrence.4,5 This is because a complete
surgical resection with tumour-free histological margins is diffi-
cult to obtain.
Anatomically, EHBD cancers are classified as perihilar and
distal bile duct cancers.4 However, tumours are rarely confined to
the short segment as bile duct cancer tends to longitudinally
spread along the bile duct wall.6,7 Recent advances in imaging
modalities and surgical strategies have improved the outcome of
the surgical treatment for EHBD cancer. A surgical resection for
EHBD cancer is determined by the location and extent of the
tumour.3,6–13
Although a pre-operative diagnosis for the extension of EHBD
cancer has improved in recent years, it is difficult to decide the
surgical resection margin pre-operatively.13,14 In some patients, a
margin positive resection was inevitable considering the opera-
tive risk. A positive resection margin has been considered an
adverse prognostic factor;6,15–24 however, the reported incidence
of a positive surgical resection margin in patients who have
undergone a resection with curative intent has varied from 9% to
as high as 74%.20,24,25 This could be explained by a variation
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between institutions or investigators on the principle of the
operation or the definition of a positive resection margin.
However, there are few reports on the long-term outcome and
factor analysis associated with survival in patients with a positive
resection margin.
The purpose of this retrospective study was to analyse the
clinicopathological features of EHBD cancer with a microscopic
positive ductal margin (MPDM) after a surgical resection, and to
explore the prognostic factors in patients with EHBD cancer with
MPDM. The clarification of whether residual carcinoma in situ
(CIS)/high-grade dysplasia (HGD) at ductal resection margins
differs prognostically from residual invasive ductal disease in
patients with EHBD cancer was also assessed.
Patients and methods
Patients and surgical procedures
With the approval from the institutional review board, all patients
with EHBD cancer who underwent a resection at Seoul National
University Hospital (SNUH) were entered into a prospectively
maintained database between 1995 and 2007.
Pre-operatively, the predominant location of the tumour and the
extent of the tumour along the biliary tract were evaluated using
imaging studies, including an enhanced computed tomography
(CT) scan, ultrasonography, magnetic resonance imaging (MRI),
cholangiography and sometimes choledochoscopy. Surgical pro-
cedures were decided by each attending surgeon with considera-
tion of the balance between the tumour extent and the safety of
each procedure. Distant metastasis, extensive lymph node metas-
tasis such as para-aortic lymph node involvement, bilateral exten-
sive intrahepatic duct infiltration, involvement of major vessels
except focal portal vein invasion and other systemic poor operative
risk factors were contraindications of a curative resection.
After a laparotomy and the exclusion of distant metastasis,
all of the following surgical procedures including a regional
lymphadenectomy at the right side of the celiac artery, and
all tissues in the hepatoduodenal ligament except the portal vein
and the hepatic artery, were removed (skeletonization of the
hepatoduodenal ligament).6 The type of resection was determined
by the location and extent of the tumour. In patients with localized
bile duct cancer in the hepatoduodenal ligament, an EHBD resec-
tion (BDR) was adopted, especially in patients in a poor general
health condition or with high-risk factors. As the tumour was
mainly located in the perihilar bile duct or involved in the liver
parenchyma, unilateral hepatic artery, or portal vein, an extended
hemihepatectomy including caudate lobectomy combined with
bile duct resection (HBR) was performed.6 When the tumour was
chiefly located in the distal bile duct, a pancreatoduodenectomy
(PD) was usually performed. Since 1991, pylorus preservation has
been attempted in all patients undergoing PD, except when duo-
denal ischaemia, duodenal ulcer or duodenal tumor infiltration
was present. A hepatopancreatoduodenectomy (HPD) was indi-
cated in patients with diffuse bile duct cancer.6
Diagnosis and definition of surgical margins
A R0 resection was defined as no residual ductal disease. Intra-
operative evaluation of the proximal (hepatic)-side and/or distal
(duodenal)-side ductal margins was performed using frozen sec-
tions among all patients. Operative specimens were submitted for
permanent histopathology. On the basis of the type of resection
procedure performed, the appropriate proximal and distal bile duct
margins were identified, and a cross-section of each was submitted
for histology. When the distal-side ductal margin was positive, addi-
tional resection of the intra-pancreatic bile duct or PD was per-
formed,as far as possible in principle.When the proximal-side ductal
margin was positive, additional resection of the hepatic duct or an
additional hepatectomy was performed where possible. Positive sur-
gical margins were classified into two categories: ‘invasive carcinoma
(IC)’and ‘CIS/ HGD’. In the present study, HGD was included in the
category of CIS owing to the extreme difficulty if distinguishing
between the two epithelial lesions.20 Radial margins were defined as
surgical margins other than the ductal margins of the resected speci-
men, but there were no isolated positive radial margins without
MPDM. Microscopic positive ductal margins were confirmed by
permanent pathological examination of a resected margin.
Comparison of clinicopathological variables in
patients with MPDM and patients follow- up
Resected specimens were submitted to the Department of Pathol-
ogy in SNUH for histological evaluation, in which experienced
hepatobiliary pathologists examined all the specimens without
knowledge of any previous diagnoses and clinical details.
Clinicopathological variables including age, gender, location of a
positive margin, histological grade and type of patient with
MPDM were evaluated. Histological findings were described in
accordance with the 7th edition TNM staging of the American
Joint Committee on Cancer (AJCC).26
Patients were followed regularly in outpatient clinics every 3–6
months, and the information during follow-up for all patients was
obtained. The sites of initial disease recurrence were determined
from cross-sectional imaging studies, such as computed tomogra-
phy or magnetic resonance imaging. They were classified as local
disease recurrence (resection margin, bilioenteric anastomosis, or
porta hepatis), regional disease recurrence (retroperitoneal lymph
nodes) and distant disease recurrence (intrahepatic, peritoneum,
or extra-abdominal sites). The overall survival was analysed from
the date of surgical resection to the date of death from all causes.
The causes of death were determined from the medical records.The
follow-up period was defined as the intervals between the date of
surgical resection and that of the last follow-up.
Adjuvant treatment
Other than for poor performance status or refusal to the chemo-
or chemoradiation, adjuvant treatment was performed after the
patients were informed of the prognosis and of the effects of each
treatment modality. Decisions were made after thorough discus-
sions with patients, physicians and each attending surgeon.
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Fluorouracil (5-FU)-based concomitant chemo-radiotherapy
(CCRT) consisted of up to 40 Gy at 2 Gy/fraction with a 2-week
planned rest, and an intravenous bolus of 5-FU (500 mg/m2/day)
given on day 1 to 3 of each split course.27 Some patients received
5-FU monthly for 1 year after radiotherapy.28 In patients treated
with chemotherapy alone, various fluoropyrimidines including
5-FU, S-1, capecitabine or uracil-tegafur were used.28
Statistical analysis
The data was analysed using SPSS® version 19.0 (SPSS Inc.,
Chicago, IL, USA). Continuous and normally distributed variables
are presented as the medians and range. Continuous parameters
in each group were compared using the independent t-test or the
Mann–Whitney U-test, and categorical parameters using the χ2
test or Fisher’s exact test. Medical records and survival data were
obtained for all patients. Survival curves were constructed using
the Kaplan–Meier method and differences in survival were evalu-
ated using the log-rank test. Multivariate analysis for prognostic
factors used Cox’s proportional hazards model. Probability (P)-
values of 0.05 or less were considered statistically significant.
Results
Clinicopathological analysis of EHBD cancer with
curative-intended resection
The clinicopathological findings in patients with EHBD cancer
with a curative-intended resection are listed in Table 1.
Clinicopathological analysis of EHBD cancer
with MPDM
A total of 124 patients were identified for MPDM after reviewing
the pathological diagnosis of resected margin, the results of which
are shown in Table 2.
Survival analysis of EHBD cancer with MPDM
The median survival (MS) and 5-year survival rate (5YSR) of R0,
R1 as CIS/ HGD, and R1 as IC were 41 months and 44.5%, 29
months and 20.7%, and 18 months and 12.0%, respectively
(Fig. 1).
In the univariate analysis, the outcome after a surgical resection
was better in patients with a ‘CIS/HGD’ ductal margin than in
those with a ‘IC’ ductal margin (Table 3 and Fig. 1). Age 60 years
or older, lymph node metastasis (N stage) and no use of adjuvant
treatment including CCRT had a marginally significant adverse
effect on survival (Table 3).
After multivariate analysis, there were two independent adverse
prognostic factors: invasive carcinoma on the resection margin
[hazard ratio (HR) = 1.66, 95% confidence intervals 1.06–2.59,
P = 0.026] and no use of adjuvant CCRT (HR = 1.57, 95% confi-
dence intervals 1.04–2.39, P = 0.033).
Ductal margin status and recurrence
Fifty-three with IC and 25 out of 124 patients with CIS/ HGD had
disease recurrence during follow-up. There were no significant
differences in local disease recurrence (25 of 85 patients, versus 14
of 39 patients, P = 0.820), regional disease recurrence (9 of 85
patients versus 6 of 39 patients, P = 0.629), distant disease recur-
rence (31 of 85 patients versus 15 of 39 patients, P = 0.616)
between IC and CIS/ HGD.
Natural course of MPDM
Figure 2 shows the clinical course of patients with MPDM. As
previously noted, the 5YSR of CIS/HGD was higher than that of
IC (Table 3 and Fig. 1). In addition, the disease-free (DF) (5YSR)
of the CIS/HGD group was higher than that of the IC group with
a statistically marginal significance. When subdividing the IC
Table 1 Patients characteristics after a curative intended resection
Characteristics Tumour location Total (n = 464) P-value
Perihilar (n = 208) Distal (n = 246) Diffuse (n = 10)
Age (years) 61.3 ± 10.7 62.9 ± 8.9 61.3 ± 7.5 62.2 ± 9.7 0.243
Gender (M : F) 154:54 175:71 6:4 335:129 0.541
Margin status
negative/ positive (%) 118/90 (43.3) 216/30 (12.2) 6/4 (40.0) 340/124 (26.9) <0.001
Histological grade
PP +WD/ MD + PLD
44:147 44:186 2:7 90:340 0.828
Operation type (n, %) <0.001
HBR 118 (56.7) 0 0 118 (25.4)
BDR 67 (32.2) 11 (4.5) 2 (20.0) 80 (17.2)
PD 14 (6.7) 234 (95.1) 7 (70.0) 255 (55.0)
HPD 9 (4.3) 1 (0.4) 1 (10.0) 11 (2.4)
Median follow-up (months) 29.0 (range 0–163.5) 38 (range 0–181.0) 22.0 (range 2.0–63.0) 32.0 (range 0–181.0) <0.001
PP, papillary carcinoma; WD, well- differentiated; MD, moderate- differentiated; PLD, poorly- differentiated carcinoma; HBR, extended hemi-
hepatectomy combined with bile duct resection; BDR, EHBD resection with lymphadenectomy; PD, pancreatoduodenectomy; HPD,
hepatopancreatoduodenectomy.
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group as treated adjuvant treatment including or excluding CCRT,
the 5YSR and DF-5YSR of the patients with adjuvant treatment
were higher than that without adjuvant treatment (5YSR 19.7
versus 2.8%, P = 0.011; DF-5YSR 16.6 versus 0%, P = 0.012)
(Fig. 2).
Discussion
The most consistent independent determinant for long-term sur-
vival after a potentially curative resection of EHBD cancer is the
surgical margin status of the resected bile duct. In consideration of
a few studies insisting that the presence of MPDM may not have an
effect on the overall mean survival,29 numerous studies have
reported an association of MPDM with a major decrease in survival
rates and an increase in recurrence rates.6,15,18–21,24 This present
study added MPDM as an adverse prognostic factor (Fig. 1).
There are several reports showing some patients undergoing a
resection with microscopic tumour involvement at the bile duct
margin survive longer than expected.6,11,20,30,31 Among these,
several studies reported CIS/HGD at the bile duct margin was
prognostically better than residual IC in patients undergoing sur-
gical resection for EHBD cancer.12,20,30,32,33 However, there are few
studies on the long-term fate and on detailed analysis for factor
associated survival in patients with a positive resection margin. In
the present study, in spite of concerns about a significant correla-
tion with IC and other features of tumour extension, IC on the
resection margin was revealed as one of the independent prognos-
tic factors after multivariate analysis. This can be explained by the
biological nature of the main tumours displaying extensive super-
ficial spread, which is likely to be responsible for the remnant
CIS/HGD at the bile duct stump, tends to be less malignant com-
pared with that of a conventional IC.33
Table 2 Patients characteristics of a microscopic positive ductal margin among a curative intended resection
Characteristics Tumour location Total
(n = 124)
P value
Perihilar (n = 90) Distal (n = 30) Diffuse (n = 4)
Age (years) 62.3 ± 10.5 65.7 ± 8.3 62.8 ± 7.8 63.1 ± 10.0 0.343
Gender (M : F) 64:26 19:11 1:3 84:40 0.130
Location of margin (+)
PRM/ DRM/ Both/ RM
a57/5/28/5 30/0/0/0 3/0/1/0 85/5/29/5 0.004
Histological Grade
PP +WD/ MD + PLD
24:60 6:21 1:2 31:83 0.789
Op type (n, %) <0.001
HBR 39 (43.3) 0 0 39 (31.5)
BDR 41 (45.6) 2 (6.7) 1 (25.0) 44 (35.5)
PD 6 (6.7) 28 (93.3) 2 (50.0) 36 (29.0)
HPD 4 (4.4) 0 1 (25.0) 5 (4.0)
Median follow-up (months) 21 (1.0–163.0) 18 (0–172.6) 9 (4.0–36.0) 20 (0–172.6) 0.380
aFive of PRM (+) among patients with perihilar bile duct cancer were revealed as combined radial margin positivity.
PRM, proximal resection margin; DRM, distal resection margin; RM, radial resection margin; PP, papillary carcinoma; WD, well- differentiated; MD,
moderate- differentiated; PLD, poorly-differentiated carcinoma; HBR, extended hemihepatectomy combined with bile duct resection; BDR, EHBD
resection with lymphadenectomy; PD, pancreatoduodenectomy; HPD, hepatopancreatoduodenectomy.
R0-CIS/HGD: P < 0.001
R0-IC: P < 0.0001
CIS/HGD-IC:  P = 0.029
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Figure 1 Overall survival in patients with extrahepatic bile duct
cancer with curative intended resection. IC, invasive carcinoma; CIS,
carcinoma in situ; HGD, high-grade dysplasia
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In spite of the slower growth, remnant CIS/HGD has the poten-
tial to develop into lethal IC. In this study, regardless of the pro-
longed survival compared to MPDM as IC, survival of MPDM as
CIS/HGD had a worse prognosis than that of the R0 resection
(Fig. 1). Thus, CIS/HGD should be completely resected to achieve
long-term survival if possible. However, when CIS/ HGD spreads
too widely, extended surgery such as HPD may be required. For
patients in a poor general condition or with high operative risk,
limited resection of the main invasive cancer with CIS/HGD
remaining at the ductal stumps, as an alternative procedure, might
bring considerable survival benefits.
Many other clinicopathological factors have been reported to
have a positive or negative impact on survival, including lymph
node metastasis,6,15,23,25,34 AJCC pT,34 histopathological grading6,8
and gender35 in resected EHBD cancer. In this study, there were no
significant differences with respect to survival based on the loca-
Table 3 Survival analysis of microscopic positive ductal margin (MPDM) among a curative intended resection in patients with extrahepatic
bile duct (EHBD) cancer
Variable No. of patients Median survival (months) P-value
Age <60/≥60 38/86 23 (1.0–163.0)/20 (1.0–172.0) 0.069
Gender Male/Female 84/40 25 (0–163.5)/18 (3.0–172.6) 0.307
aT stage T1/T2/T3 19/53/52 29 (1.0–123.0)/20 (3.0–143.7)/18 (0–172.6) 0.657
aN stage N0/N1 89/35 25 (1.0–172.6)/16 (0–163.5) 0.097
Tumour location Perihilar/Distal/Diffuse 90/30/4 21 (1.0–163.5)/18 (0–172.6)/9 (4.0–36.0) 0.475
bDifferentiation PP + WD/MD + PLD 33/86 32 (0–151.0)/18 (1.0–172.6) 0.246
Perineural invasion Not identified/Present 41/83 36 (1.0–72.9)/20 (0–172.6) 0.216
Resection margin IC/CIS + HG 85/39 18 (0–172.6)/29 (1.0–151.0) 0.029
Type of operation HBR/BDR/PD/HPD 39/44/36/5 20 (1.0–163.5)/25 (3.0–143.7)/
23 (0–172.6)/13 (2.0–40.0)
0.264
Adjuvant treatment No/Yes 54/70 18 (0–151.0)/21 (4.0–172.6) 0.078
Chemotherapy alone No/Yes 54/6 18 (2.0–72.9)/16 (4.0–172.6) 0.866
CCRT No/Yes 61/63 18 (2.0–64.0)/21 (5.0–163.5) 0.065
Values in parenthesis are range of follow-up.
aAJCC 7th edition.
bThe pathological reports of five patients did not contain the histological differentiation.
PP, papillary carcinoma; WD, well-differentiated; MD, moderate-differentiated; PLD, poorly-differentiated carcinoma; HBR, extended hemihepatec-
tomy combined with bile duct resection; BDR, EHBD resection with lymphadenectomy; PD, pancreatoduodenectomy; HPD, hepatopancreato-
duodenectomy; CCRT, concomitant chemo-radiotherapy.
Microscopic margin
positive
Invasive
carcinoma
No adjuvant
treatment
Adjuvant
treatment
Adjuvant
treatment
No adjuvant
treatment
Carcinoma in situ or
high-grade dysplasia
No. of patients = 124
5YSR =13.6%
DF-5YSR = 13.1%
No. of patients = 39
5YSR = 20.7%
DF-5YSR = 19.5%
No. of patients = 85
5YSR = 12.0%
DF-5YSR = 10.8%
No. of patients = 48
5YSR = 19.7%
DF-5YSR = 16.6%
No. of patients = 37
5YSR = 2.8%
DF-5YSR = 0%
No. of patients = 21
5YSR = 22.9%
DF-5YSR = 20.3%
No. of patients = 18
5YSR = 21.5%
DF-5YSR = 15.2%
P = 0.029
P = 0.066
P = 0.011
P = 0.012
P = 0.910
P = 0.724
Figure 2 Clinical course of patients with microscopic positive ductal margin. 5YSR, 5-year survival rate; DF-5YSR, disease-free 5-year
survival rate
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tion of the tumour or resection type, suggesting that once the
microscopic remnant tumour has occurred, the prognoses of dif-
ferent locational types are similar (Table 3). These results were
similar to Jang et al. 6 where they reported on the actual long-term
outcome of EHBD cancer after a surgical resection.
There has been controversy whether remnant CIS/HGD at the
bile duct stump develops into IC. Jang et al. 6 previously reported
that, in attempted curative surgery, microscopic tumor involvement
in the resection margin did not always mean early recurrence.
However, there are several reports that show a significant relation-
ship between local recurrence and ductal margin status.12,20,30,32,33
Furthermore, some studies suggested residual CIS may cause late
local disease recurrences, whereas residual invasive ductal lesions
cause early local recurrences.20,36 In this study, 14 out of 39 patients
with CIS/HGD showed local recurrence at the bile duct stump, such
as, bilioenteric anastomosis, or porta hepatis. However, this result
did not have any statistical difference in the local recurrence rate in
patients with IC (25 out of 85 patients, P = 0.820). As a result,
it could be possible that CIS/HGD has the potential to progress
to IC.
Even although there is a possibility for CIS/HGD to develop into
IC, there are differences in their biological behaviours. Remnant
CIS/HGD is likely to develop into IC in the late phase after surgery.
In this study, the DF-5YSR of the CIS/HGD group was significantly
higher than that of the IC group (Fig. 2), suggesting that CIS/ HGD
had less malignancy and showed slower growth than IC. In spite of
the similar incidence of recurrence, it is noteworthy that a ductal
margin with CIS/ HGD resulted in a prolonged disease-free sur-
vival than that of a ductal margin with IC. Therefore, as mentioned
above, for patients in a poor general condition or with high opera-
tive risk, limited resection of the main invasive cancer with CIS/
HGD remaining at the ductal stumps, as an alternative procedure,
may bring considerable survival benefits.37
Gawk et al. 31 suggested that adjuvant radiotherapy might be
useful in patients with EHBD cancer, especially for those patients
with microscopic residual tumours and positive lymph nodes after
resection for increasing local control In this study, there was
no survival benefit with adjuvant chemotherapy alone but an
increase in survival in patients with MPDM who received CCRT
with marginal significance (Table 3), especially the patients with
an IC resection margin (Fig. 2). In spite of this study has the
limitation that the post-operative adjuvant treatment was given to
selected patients and the treatment regimens differed significantly
among the individuals, some subsets of patients with a positive
margin could have a better prognosis if chemoradiotherapy is
combined with a surgical resection.6,10,31
In conclusion, among patients undergoing a surgical resection
for EHBD cancer, IC at the ductal resection margins appears to
have a more adverse effect on survival, whereas residual CIS or
HGD does not. It is therefore clear that when the ductal resection
margin status is positive upon pathological examination, dis-
crimination between CIS/ HGD and IC is clinically important,
and a resection should be considered and efforts should be made
to obtain an IC-free margin. For MPDM, especially IC, adjuvant
chemoradiation can be beneficial.
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